IMMUNOVANT INC (IMVT) Stock Price, Quote, News and Overview
NASDAQ:IMVT - Nasdaq - US45258J1025 - Common Stock - Currency: USD
IMVT Quote, Performance and Key Statistics
IMMUNOVANT INC
NASDAQ:IMVT (2/4/2025, 8:00:02 PM)
Premarket: 20.97 +0.06 (+0.29%)20.91
+0.11 (+0.53%)
The current stock price of IMVT is 20.91 USD. In the past month the price decreased by -15.72%. In the past year, price decreased by -41.1%.
IMVT Latest News, Press Releases and Analysis
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm
/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT)...
Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024
Five Investigational New Drug (IND) applications cleared across a range of therapeutic areas and FDA divisions for lead asset, IMVT-1402Proof of concept...
Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting
NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for...
Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases
Amgen tested its drug, Uplizna, in generalized myasthenia gravis, a market where Argenx's Vyvgart leads.
What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?
Immunovant reports promising Phase 2a trial results for batoclimab in treating Graves' Disease, showing a high response rate and significant IgG reduction. A pivotal trial is expected to start by the end of 2024.
IMVT Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.77 | 335.67B | ||
| AMGN | AMGEN INC | 14.58 | 155.36B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 945.65 | 124.20B | ||
| GILD | GILEAD SCIENCES INC | 22.12 | 122.12B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.27 | 76.60B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.95B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.95B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.08B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.76B | ||
| NTRA | NATERA INC | N/A | 23.00B | ||
| BIIB | BIOGEN INC | 8.73 | 20.76B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.52 | 15.78B |
Related stock screener links
About IMVT
Company Profile
Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. The company is headquartered in New York City, New York and currently employs 207 full-time employees. The company went IPO on 2019-05-14. The firm is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. The company is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD). Its lead product candidate IMVT-1402 has also been observed to reduce IgG antibody levels in a Phase I clinical trial conducted in healthy adults. IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn.
Company Info
IMMUNOVANT INC
320 West 37Th Street
New York City NEW YORK 10018 US
CEO: Peter Salzmann
Employees: 207
Company Website: https://immunovant.com/
Investor Relations: https://www.immunovant.com/investors
Phone: 19175803099
IMVT FAQ
What is the stock price of IMVT?
The current stock price of IMVT is 20.91 USD.
What is the symbol for IMMUNOVANT INC stock?
The exchange symbol of IMMUNOVANT INC is IMVT and it is listed on the Nasdaq exchange.
On which exchange is IMVT stock listed?
IMVT stock is listed on the Nasdaq exchange.
Is IMVT a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for IMVT, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of IMVT.
Does IMVT stock pay dividends?
IMVT does not pay a dividend.
When does IMVT stock report earnings?
IMVT will report earnings on 2025-02-10, after the market close.
What is the Price/Earnings (PE) ratio of IMVT?
IMVT does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.22).
What is the Short Interest ratio of IMVT stock?
The outstanding short interest for IMVT is 20.62% of its float.
IMVT Technical Analysis
IMVT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IMVT. While IMVT has a great health rating, there are worries on its profitability.
IMVT Financial Highlights
Over the last trailing twelve months IMVT reported a non-GAAP Earnings per Share(EPS) of -2.22. The EPS decreased by -12.69% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -62.63% | ||
| ROE | -71.93% | ||
| Debt/Equity | 0 |
IMVT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 88% to IMVT. The Buy consensus is the average rating of analysts ratings from 20 analysts.